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Abstract 
African swine fever virus (ASFV) causes a highly contagious and deadly disease in 
swine, with severe economic consequences. In the absence of a vaccine, control measures that 
target ASFV replication steps are being actively pursued. Due to the high risk of ASFV and its 
foreign animal disease status, in the United States it is regulated as a select agent and requires 
BSL-3 containment. In addition, virulent strains of ASFV require primary cells for propagation 
in tissue culture. In the face of these limitations the ability to use less restrictive surrogate viruses 
is attractive. One such option is Vaccinia virus (VV), a member of family Poxviridae. Though 
VV has been used in this capacity before, investigation into its use in Vero cells are limited. 
When examined using Vero cells treated with various chemical inhibitors, VV produced similar 
results as the Vero cell adapted strain of ASFV, suggesting the two viruses behave similar during 
cell entry and early infection. VV provides a suitable surrogate virus for ASFV research, as well 
as a virus that can replicate in both Vero cells and primary swine macrophages, though there are 
limited studies regarding the latter.  
Swine macrophages and monocytes are the primary target cells for ASFV infection, 
though factors responsible for this tropism are unknown. A significant body of work identified 
CD163 as required for ASFV cell entry; however, macrophages lacking CD163 and CD163 
knockout pigs support infection. ASFV also utilizes macropinocytosis, a non-specific cellular 
uptake pathway, to enter the cell. This may explain why CD163KO pigs can be infected with 
ASFV. The present data indicates that CD163 is not required for ASFV infection, but does not 
rule out its involvement entirely.  
 Macropinocytosis inhibitors used in all experiments included EIPA, cytochalasin D, and 
wortmannin. Inhibitors of clathrin-mediated endocytosis included chlorpromazine and dynasore. 
  
ML-7 inhibits myosin light chain kinase and nocodazole inhibits microtubule dynamics. All 
seven inhibitors reduced the infection rate, consistent with ASFV using both macropinocytosis 
and clathrin- and dynamin-dependent endocytosis, as well as non-muscle myosin II and 
microtubules during stages of entry and early infection. However, the inhibitor effects were not 
significantly different between wildtype and CD163KO macrophages, suggesting that CD163 
lacks involvement with ASFV infection. This work provides a framework for VV as an early 
infection surrogate model in Vero cells, and helps close the door on the CD163 controversy.  
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Chapter 1 - Overview of African swine fever and current challenges 
 Introduction 
Pork is big business in the United States, with pork exports in 2018 exceeding 5 billion 
pounds (USDA, 2019b). A foreign animal disease event, such as the introduction of African 
swine fever virus (ASFV) would greatly impact this number.  
African swine fever was first described in Kenya in 1921 following introduction of the 
domestic pig into the country in 1910. Early transmission studies conducted by Montgomery in 
1914 and 1916 found that wild African suids such as warthogs (Phacochoerus africanus) can 
become infected and harbor virus in blood without showing clinical disease. These studies also 
showed that transmission can occur between domestic pigs via excretions such as urine and 
feces. Virus in biological materials is persistent in the environment, with naïve pigs becoming 
infected when placed in a pen that was not cleaned after housing infected animals. While ASFV 
spreads readily between domestic pigs via direct contact, this does not seem to be the case 
between warthogs, and from warthogs to domestic pigs (Eustace Montgomery, 1921). It was 
determined that vector borne transmission by soft ticks is crucial for maintenance of the virus in 
warthog populations, as well as a potential route of spillover into domestic pig populations 
(Parker et al., 1969). In sub-Saharan Africa, the sylvatic transmission cycle between warthogs 
and soft ticks of the genus Ornithodoros generally goes unnoticed. These nidicolous ticks inhabit 
warthog burrows and can transmit the virus to juvenile warthogs, which develop a transient 
viremia. In ten surveyed areas throughout southern and eastern Africa where tick vectors are 
present, greater than 80% of the sampled warthog population tested positive for antibodies to 
ASFV (Plowright W., Thomson G. R. et al., 1994). A domestic pig-tick cycle has been described 
in areas where soft ticks are present, such as Malawi, Portugal, and Spain. However, in other 
regions such as west Africa, the role of soft ticks has not been described. The disease remained 
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confined to Africa until transcontinental spread of contaminated waste brought the disease to 
Portugal in 1957. This situation was controlled until a second incursion in 1960 started an 
epidemic which lasted over 30 years (Costard et al., 2013). By 1985 ASF had entered France, 
Italy, Belgium, the Netherlands, Brazil, Cuba, the Dominican Republic, and Haiti (Arias et al., 
2008). Control measures were successful, though extreme. For example, the island of Hispaniola 
was completely depopulated of swine. In Haiti alone almost 400,000 pigs were slaughtered 
during a campaign costing upwards of 15 million USD (Alexander, 1992). Arias et al recently 
reassessed the eradication effort Spain launched in 1985. Spain’s coordinated plan introduced 
mobile veterinary teams, serologic surveillance of all pig farms, improvements in animal holding 
facilities, depopulation of infected herds, and strict regulation involving animal movement. 
Protection and surveillance zones were established in response to an outbreak, and about one 
month following a herd depopulation affected buildings were completely disinfected and all 
animal products and feed destroyed. Farms were not repopulated until healthy sentinel animals 
introduced to the premises remained serologically negative. While this program was successful it 
involved many years of continued effort, a large budget, and producer compliance. As progress 
was made, establishing regions (ASF-free region, ASF infected-region, Surveillance region) 
allowed trade prohibitions to be gradually lifted (Arias et al., 2008). Two lessons from the 
Spanish model are the necessity of farmer education and cooperation, and the importance of 
establishing defined zones to minimize impact on trade. France, Italy, Belgium, and the 
Netherlands were also successful at eradicating the disease, with the exception of the island of 
Sardinia where the disease remains endemic. Brazil implemented a similar emergency plan that 
led to eradication of the disease over a ten year period and the culling of nearly 67,000 animals 
(Lyra, 2006). By the late 1990s South America and the Caribbean were declared ASF free.  
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On May 22, 2007 the Republic of Georgia notified the OIE of a swine disease outbreak 
thought to be post-weaning multisystemic wasting syndrome. On June 4th the OIE reference 
laboratory in Pirbright confirmed a diagnosis of ASFV. The likely source is contaminated waste 
brought in on ships to the Port of Poti from eastern Africa. The outbreak spread rapidly, with 56 
out of 61 Georgian districts affected by July 2007 (Rowlands et al., 2008). Backyard pig farms 
and free range pigs with access to untreated swill and garbage likely contributed to the spread of 
disease and allowed for spillover into the wild boar population. Wild boar have also played a key 
role in the spread of ASF in Europe, though their role in ASF epidemiology in Asia remains less 
understood. By late 2007 the disease had entered Russia, with wild boars near Chechnya testing 
positive for the virus. By 2008 the disease had entered Armenia and Azerbaijan (Rowlands et al., 
2008). In 2014 ASF entered the European Union and to date cases have been reported in the EU 
Baltic states, Romania, Bulgaria, Hungary, and Belgium. In August 2018 the first reports of ASF 
came from China. The exact origins are unknown, but the virus is genetically identical to the 
genotype II isolates circulating in Russia, The Ukraine, and the Caucasus (Zhou et al., 2018). 
ASF entering China was particularly concerning, because with over 50% of the global pig 
population China is the single largest pig producing country in the world. The US also has 
significant trade involvement with China and imports millions of kilograms of feed ingredients 
and animal products every year. As seen in Figure 1.1, ASF spread through China at an alarming 
rate with most provinces affected in a matter of months. The Chinese pork industry has suffered 
as a result, with shortages leading to significant price fluctuations. The USDA estimates that 
2020 Chinese pork production will decrease 25% and imports increase 35% compared to 2019. 
This is also a threat to the global supply of the blood thinning medication heparin, roughly 80% 
of which comes from Chinese swine (Vilanova et al., 2019). Since then, ASF has been reported 
in Mongolia, Vietnam, Cambodia, and North Korea. On June 20, 2019, the first outbreak of ASF 
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in Laos was confirmed and the disease was reported in Serbia for the first time in August 2019. 
A pattern of rapid spread similar to what occurred in China is being seen in other Asian 
countries, such as in Vietnam (Figure 1.2). As the epidemic continues, movement of animals and 
animal products, both legally and illegally, or deliberate introduction of ASFV as an act of 
bioterrorism are the most likely risks to the US. USDA APHIS regulates the handling and 
disposal of international garbage and controls restrictions on the importation of animal products. 
Products, byproducts, and animal feed are allowed to be imported from ASF-endemic areas 
provided they are treated in a manner proven to destroy the virus (Brown & Bevins, 2018). 
Products coming from regions designated as low risk can be raw, provided documentation of the 
region and herd of origin is provided. Despite a complex regulatory system, large numbers of 
products are illegally smuggled into the US every year. Between 2012 and 2016 over 68,000 
items were seized by US Customs and Border Protection (USCBP), but it is likely that only a 
small subset of contraband is detected (Brown & Bevins, 2018). USCBP also announced on 
March 15, 2019 that at the Newark port of entry a seizure was conducted of 50 shipping 
containers holding approximately 1 million pounds of pork products illegally shipped from 
China. In other ASFV-negative countries, such as Australia and Japan, ASFV has been identified 
in pork products smuggled by air passengers. Such incidents emphasize the risk of ASFV 
transcontinental spread and the need for the enforcement of trade and travel regulations. The US 
should focus resources not only on ASF mitigation strategies, but also on addressing the effects 
on economics and trade resulting from the global epidemic.  
 The virus 
African swine fever virus is a large double-stranded DNA virus and the sole member of the 
family Asfarviridae (International Committee on Taxonomy of Viruses. et al., 1995). The virion 
is 200nm in diameter and has a 170 to 190Kb genome. The genome contains between 151 and 
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167 open reading frames, though about half of ASFV genes lack a known function (Alejo et al., 
2018). Several concentric domains compose the mature virus, including an outer envelope, 
capsid, inner envelope, core shell, and nucleoid (Salas & Andrés, 2013). The outer envelope, 
which contains the CD2v (EP402R) transmembrane protein, is host derived and acquired during 
budding from the cell (S. S. Breese & Pan, 1978; Sydney S. Breese & DeBoer, 1966). CD2v is a 
viral homologue of the cellular CD2 protein and binds erythrocytes causing viral hemadsorption 
(Rodríguez et al., 1993). The capsid is the location of the highly immunogenic major capsid 
protein p72 (Salas & Andrés, 2013). Based on DNA sequencing of the capsid p72 gene (B646L), 
along with B602L, E183L (p54), and CP204L (p30), ASFV is divided into 24 genotypes (Bastos 
et al., 2003; Quembo et al., 2018). Based on CD2v and C-type lectin (EP153R), ASFV can also 
be placed in eight separate serological groups (Malogolovkin et al., 2015). While CD2v is the 
only viral protein decidedly located at the outer envelope, some host proteins such as CD9 and 
integrin beta 1 are also detectable. CD9 and integrin beta 1 are two of 21 host proteins identified 
in ASFV, most of which normally localize to the cell surface (Alejo et al., 2018). These virus-
packaged host proteins may contribute to evasion of host immunity, but it has been observed that 
the outer envelope is not necessary for infection. Several proteins with roles in viral assembly 
and entry localize at the inner envelope including: p17 (pD117L), p54 (pE183L), p12 (pO61R), 
p22 (pKP177L), pH108R, pE199L and pE248R (Alejo et al., 2018). p54, a type I transmembrane 
protein, is crucial for the formation of the inner envelope, while p17 is required for assembly of 
the capsid on top of the inner envelope (J. M. Rodriguez et al., 2004; Suarez et al., 2010). The 
uneven distribution of proteins between the inner and outer envelops supports the notion that the 
inner envelope is structurally and functionally more significant than the outer envelope during 
viral replication. Within the inner envelope is the core shell, a thick layer comprised of several 
proteins originating from two polyproteins pp220 (pCP2475L) and pp62 (pCP530R) (Alejo & 
6 
Salas, 2002). The protein S273R proteolytically cleaves these two polyproteins to yield their 
mature products. These include the late viral proteins p150, p37, p34, p14, p5 from pp220 and 
p35, p15, p8 from pp62 (Alejo et al., 2018). Though viral replication primarily takes place in 
cytoplasmic viral factories, ASFV undergoes a crucial nuclear step as determined by the failure 
of enucleated cells to support virus replication (Ortin & Vińuela, 1977). At least one viral protein 
(p37) and viral DNA are found in the nucleus during early infection, but localize exclusively to 
the cytoplasm at later times (Eulálio et al., 2007). Further information about nucleus involvement 
during infection and ways this pathway could be manipulated to interrupt infection are unknown. 
The first major step of morphogenesis is the formation of the inner envelope, which is assembled 
from endoplasmic reticulum derived membrane fragments (Germán Andrés et al., 1998; Rouiller 
et al., 1998). The capsid and core shell are assembled concomitantly, with the capsid relying on 
the non-structural capsid assembly protein pB602L (Cobbold & Wileman, 1998; Epifano et al., 
2006). Formed icosahedral particles both with and without the dense central nucleoid can be seen 
within viral factories, suggesting it is likely the last step of assembly (Salas & Andrés, 2013). 
Mature virions exit the cell by budding, though lysis of cells also leads to the release of 
structurally different, but still infectious, intracellular mature virions (G Andrés et al., 2001). 
 Host-virus interactions 
Host-virus interactions are the basis for pathogenesis and host immune response, with 
outcomes of ASFV infection varying markedly depending on this intricate network. Studying 
these interactions is important to identify steps that are crucial for viral replication and potential 
targets for vaccines or treatments. ASFV primarily replicates in monocytes and macrophages, but 
receptors involved in tropism and cell entry are unknown. There are conflicting reports on the 
involvement of the macrophage scavenger receptor CD163 during ASFV cell entry. Sánchez-
Torres et al reported that, when sorted, a CD163+ population of monocytes demonstrated higher 
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permissiveness to ASFV infection than the CD163- group (Sánchez-Torres et al., 2003). Yet, a 
study by another group in 2014 reported that expression of exogenous CD163 did not increase 
infection rates, nor allow for infection in normally non-permissive cell lines (Lithgow et al., 
2014). In addition, genetically edited pigs lacking CD163 show no resistance to the virus 
(Popescu et al., 2017). Together, these findings do not exclude the possibility that CD163 plays a 
role in ASFV infection, but suggests it is not imperative for infection. Beyond CD163, the 
existence of subpopulations of monocytes/macrophages with different expression patterns has 
not been evaluated as thoroughly in swine as in humans. If such subpopulations exist it is 
possible they may affect susceptibility to ASFV. There are likely factor(s) yet to be determined 
that are responsible for ASFV’s tropism for porcine macrophages. 
Once inside the cell, the first feat is simply surviving the harsh environment of a 
macrophage. ASFV utilizes a base excision repair pathway to help offset the effects of oxidative 
damage (Garcı́a-Escudero et al., 2003). One of the main targets of immune modulation by the 
virus is interferon production and response. ASFV has several genes that function to inhibit 
interferon response, namely belonging to two multigene families, MGF360 and MGF 505/530 
(Afonso et al., 2004). Permissiveness to infection in cells pretreated with IFN I supports the 
notion that the virus also modulates cellular responses to IFN I and prevents induction of the 
antiviral state (Golding et al., 2016). Inhibiting apoptosis is another common viral strategy seen 
during ASFV infection. The virus has several known anti-apoptotic proteins, including a bcl-2-
like protein A179L, inhibitor of apoptosis protein A224L, and p53 effector protein pE153R  
(Afonso et al., 1996; Hurtado et al., 2004; Nogal et al., 2001). Delaying apoptosis allows for 
prolonged viral replication, though in later stages of infection there is a shift towards a pro-
apoptotic state. ASFV also inhibits host inflammatory responses. ASFV pA238L downregulates 
the TNF-α and COX-2 inflammatory pathways (Granja et al., 2009). CD2v is reported to both 
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inhibit host immunity and enhance virulence and is also responsible for viral hemadsorption (M 
V Borca et al., 1998; Pérez-Núñez et al., 2015). While progress has been made in understanding 
host-virus interactions, many pieces of information are missing such as barriers to infection and 
the functions and mechanisms of action of viral proteins.  
 ASFV vaccines 
The lack of an effective vaccine for ASF presents a significant challenge for disease 
control efforts. The observation that pigs surviving ASF are able to develop protective immunity 
gives hope that a safe and effective vaccine may be possible, but research to date has not yielded 
a product fit for use in production. Our incomplete understanding of factors that confer immunity 
to ASFV is a significant barrier to vaccine development. There is a lack of basic knowledge 
about the general mechanisms of virus neutralization, as well as controversy about the role of 
neutralizing antibodies during ASFV infection. Studies performed over the last 50 years, 
including a trial using modern adjuvants, have shown that traditional inactivated vaccines fail to 
induce protection against ASFV infection (Blome et al., 2014; Forman et al., 1982; Stone & 
Hess, 1967). A number of vaccine strategies have been tested including DNA vaccines and viral 
vectors, with mixed results. A DNA vaccine encoding p30 and p54 fused with the extracellular 
domain of CD2v induced an immune response, but was not protective. However, the addition of 
ubiquitin expressed along with the same three viral proteins did confer partial protection in the 
absence of specific antibodies (Argilaguet et al., 2012; Lacasta et al., 2014). Viral vector 
vaccines utilizing different platforms such as modified vaccinia Ankara, alphaviruses, and 
adenoviruses have been found to generate specific antibody and T-cell response (Jancovich et al., 
2018; Lokhandwala et al., 2017; Lopera-Madrid et al., 2017). When placed into pigs though, 
these preparations were not found to confer protection against challenge with virulent virus 
(Jancovich et al., 2018; Lokhandwala et al., 2019; Netherton et al., 2019). In addition, an 
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accelerated clinical course sometimes observed following vaccination suggests the possibility of 
antibody dependent enhancement of infection (Blome et al., 2014; Escribano et al., 2013; 
Sunwoo et al., 2019). Currently, live attenuated vaccines (LAV) show the most promise, albeit 
with barriers to practical use in the field. Several studies demonstrate LAV induced protection 
against virulent challenge. Two deletion mutant viruses, one lacking six genes of the 
MGF360/505 families and the other lacking the virulence associated gene 9GL (B119L), are 
capable of conferring protection against challenge with parenteral virus (O’Donnell, Holinka, 
Gladue, et al., 2015; O’Donnell, Holinka, Krug, et al., 2015). Interestingly, an isolate harboring 
both of these deletions was not protective, likely due to further attenuation and decreased 
replication (O’Donnell et al., 2016). In contrast, vaccination with a virus lacking both the 9GL 
and UK (DP96R) genes led to protection against clinical disease, though replication of the 
parental challenge virus was not impeded (O’Donnell et al., 2017). Despite some promising 
results there are several hurdles preventing practical use of LAVs in the field including: 
prolonged shedding of the vaccine virus, risk of return to virulence, vaccine associated sequelae, 
mixed levels of protection against heterologous viruses, and the necessity of a companion test to 
differentiate vaccinated and infected animals. Recently, it was reported that an attenuated virus 
utilizing ASFV Georgia07 lacking the I177L gene provided complete protection from challenge 
with the virulent parental strain (Manuel V Borca et al., 2020). Due to the complete protection 
from the epidemiologically relevant Georgia07 strain, lack of vaccine associated side effects, the 
ASFV-G-ΔI177L strain shows encouraging results as a vaccine candidate. Further research and 
field testing is needed to define the target antigens and the immune mechanisms involved with 
protection from ASFV infection, and to balance effectiveness and safety of new vaccines. 
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 ASFV therapeutics and antivirals 
In the absence of a vaccine, alternative therapies continue to be evaluated. While more than 90 
antiviral drugs are available for use today, there remain many viruses with no functional 
treatment (E de Clercq & E., 2016). Nucleoside antiviral drugs such as cidofovir, pyrazofurin, 
and ribavirin, have shown in-vitro inhibition of ASFV (Erik De Clercq et al., 1986; Erik De 
Clercq, 2002). These nucleoside analogues are used in humans against DNA viruses such as 
HSV-1 and poxviruses, but their effects in pigs are unknown and cost is a likely barrier for their 
use. Several compounds have demonstrated the ability to partially inhibit ASFV replication in-
vitro, such as flavonoids including apigenein, genkwanin, and genistein (Arabyan et al., 2018; 
Hakobyan et al., 2016, 2019). These authors reported that flavonoids are able to disrupt viral 
DNA replication and tubulin assembly. Flavinoids are naturally occurring secondary metabolites 
found in many plants and plant products such as fruits, nuts, seeds, wine, and tea. 
Fluoroquinolones have also shown in-vitro antiviral activity against ASFV (Mottola et al., 2013). 
While the antiviral properties of genkwanin and genistein were tested on primary macrophages, 
most of these experiments were performed in Vero cells using the tissue culture adapted strain, 
and none have been tested in-vivo. Cost is always an important limitation of diseases of food 
animals, as treatment price should not exceed the value of the animal. For this reason, less 
expensive naturally occurring compounds have more use potential. Another consideration for 
practical use of therapeutics is determining the time point at which treatment will be instigated. It 
has been observed that viral shedding begins about the same time point as the onset of clinical 
signs, suggesting that successful detection and treatment of infected animals prior to 
contagiousness may be unlikely (Davies et al., 2017; Guinat et al., 2014). Preemptive herd 
treatment instituted at surrounding farms during an outbreak to provide a security zone may be 
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the most judicious use. ASF outbreak situations remain difficult to control with our reliance on 
less than ideal strategies such as stamping out, quarantine, and trade restrictions. 
 Transmission 
Another challenge of managing the spread of ASF comes from its use of several 
transmission pathways. The disease can spread by direct or indirect contact between pigs, on 
fomites and mechanical vectors, in contaminated feed and water, and via soft ticks (Guinat et al., 
2014; Plowright et al., 1969). Appearance of severe disease occurs when the virus escapes the 
naturally occurring sylvatic cycle between ticks and African pigs and enters a population of 
domestic pigs or wild boar. While infection through direct contact between warthogs and 
domestic pigs has not been documented, if domestic swine access an improperly disposed 
carcass or are fed contaminated warthog products, infection may result (Thomson et al., 1980). 
Warthogs may also transport infected Ornithodoros ticks from burrows to areas inhabited by 
domestic pigs, leading to exposure (Horak et al., 1983). While efficacy of experimental infection 
varies notably between strains and routes of exposure, once established in a population the virus 
is readily transmissible between domestic pigs. This spread occurs primarily through direct 
contact involving the oral-nasal route or wounds. Table 1.2 shows the infectivity of various doses 
and strains of ASFV when administered to pigs orally, nasally, or intraoropharyngeally. There is 
concern that a disease introduction event may lead to the establishment of an endemic cycle in 
the US due to the presence of both a large population of feral swine and native species of soft 
ticks. 
 Feral swine in the United States 
The United States Department of Agriculture (USDA) Animal and Plant Health 
Inspection Service (APHIS) estimates that over 6 million feral swine exist in at least 35 states. 
Sus scrofa (includes both the Eurasian wild boar and feral pigs) and Sus scrofa domesticus are 
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highly susceptible to ASF. While transmission models of ASF involving wild boar are 
incomplete, it is understood that they continue to play a key role in the spread and persistence of 
ASF in Europe. Epidemiological studies suggest that disease incidence in local wild boar 
populations is a significant risk factor for farms becoming infected (Halasa et al., 2019; Nurmoja 
et al., 2018). However, both wild boar population density and environmental conditions should 
be considered when evaluating virus persistence. Cold and humid environments promote virus 
longevity in the environment, with some suggesting that contaminated carcasses are a more 
significant transmission concern than live animals (EFSA, 2015). If population density is a less 
important transmission factor, controlling feral swine movement may be an important strategy in 
addition to population control. Monitoring of feral swine behavior shows these animals will seek 
out interactions with domestic pigs if possible, and feral pigs are also more likely than their 
domestic counterparts to have access to landfills or other potentially contaminated sources of 
food waste (Herrera-Ibatá et al., 2017; Wyckoff et al., 2009). Historically, fencing has been used 
successfully to control feral swine movements in national parks and some countries (such as 
Denmark) are currently constructing fences to control wild boar movement (Hone & Stone, 
1989; McCann & Garcelon, 2008). Unfortunately, the size of the US and the scale of the feral 
swine problem may make this an impractical solution. An additional consideration is the impact 
of expansive fencing on wildlife and resistance to such a project from environmentalists. 
Management of wild boar populations is challenging due to their high reproductive rate and a 
population’s tendency to disperse in response to extensive hunting efforts. A combination of 
tactics such as baiting, trapping, and hunting feral swine can be applied to control the population 
and animal movements. In June 2019 the USDA allocated $75 million to the Feral swine 
eradication and control pilot program (FSCP), a joint project between the USDA’s Natural 
Resources Conservation Service and APHIS. The project will work with landowners in target 
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areas to remove feral swine, restore damage done by feral swine, and provide continued 
assistance for feral swine control to producers.  
 Vector-borne transmission 
Ornithodoros is one of the five genera in family Argasidae, which is comprised of about 
200 species of soft ticks (Guglielmone, 2010). ASFV is maintained in Africa in a sylvatic cycle 
between juvenile warthogs and soft ticks of species O. porcinus porcinus which inhabit burrows 
(Plowright et al., 1969). After 1979 the O. moubata complex was divided into four distinct 
species, including O. porcinus (Walton, 1979). Once a tick is infected, viral replication occurs in 
a number of tissues, including the midgut (Kleiboeker et al., 1998, 1999). O. porcinus ticks are 
capable of harboring104 to 106 HAD50/tick, with no effect to the tick, except during the stress of 
oviposition (Kleiboeker et al., 1998; Plowright W., Thomson G. R. et al., 1994; Wilkinson et al., 
1988). In other tick species, such as O. coriaceus, increased nymph mortality is observed.  The 
two most likely routes of virus transmission to swine are through tick saliva or coxal fluid 
(Kleiboeker et al., 1998; Plowright et al., 1970). The United States is host to several species of 
Ornithodoros ticks including O. coriaceus, O. parkeri, and O. turicata. Two species, O. 
coriaceus and O. turicata, are able to transmit ASFV to domestic pigs (Cooley & Kohls, 1944; 
Groocock et al., 1980; Hess et al., 1987). O. puertoricensis is a species found in the Caribbean 
and is also a competent vector for ASFV (Endris et al., 1991, 1992). A number of soft tick 
species exist in the US that have not been evaluated for ASFV competence including: Argas 
sanchezi, A. radiatus, A. persicus, A. giganteus, A. brevipes, A. ricei, A. miniatus, A. 
monolakensis, Carios capensis, C. denmarki, Otobius megnini, Otobius lagophilus, 
Ornithodoros kelleyi, O. hermsi, O. concanensis, O. stageri, O. talaje, O. yumatensis, O. 
sparnus, O. coprophilus, O. dyeri, O. rossi, O. dugesi, and O. quilae (Cooley & Kohls, 1944; 
Donaldson et al., 2016). Based on documented geographic range and vector-host interactions 
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many of these ticks may be considered low risk for ASFV transmission, but they can’t be 
completely ruled out as a transmission risk (Golnar et al., 2019). Soft ticks contribute to disease 
persistence by their ability to harbor and transmit ASFV for five years or more, as well as the 
ability of some species such as O. porcinus to maintain it independently of swine via transstadial 
and transovarian transmission (Boinas et al., 2011; Hess et al., 1989; Plowright W., Thomson G. 
R. et al., 1994). O. coriaceus is capable of transstadial transmission, but O. parkeri and O. 
turicata have not been evaluated for these traits. In the Iberian peninsula, the presence of the 
competent vector O. erraticus (also known as O. marocanus) complicated disease eradication 
efforts (Plowright W., Thomson G. R. et al., 1994). The presence of infected ticks necessitates 
drastic changes to disease control methods. For example, current EU directives increase the 
mandated quarantine period of a farm from 40 days after an outbreak is controlled to six years if 
tick vectors are present. The entry of ASFV into the soft tick population in the US holds the 
potential to markedly increase the difficulty of disease control.  
 Variable clinical disease presentation and carrier animals 
African swine fever clinical presentation can be distinctly different depending on virus 
and host factors, with chronic or persistent disease more challenging to detect. When highly 
virulent strains such as Georgia07 are introduced into naïve animals, acute disease with high 
mortality is seen. Clinical signs of acute disease include pyrexia, crowding behavior, depression, 
anorexia, dyspnea, coughing, nasal discharge, erythema, cyanosis, epistaxis, vomiting, mucoid to 
bloody diarrhea, and abortion (Gómez-Villamandos et al., 2013; Sánchez-Vizcaíno et al., 2015). 
Mortality of acute disease approaches 100% within 4-8 days, with typical gross pathologic 
changes including ascites, hepatic and biliary congestion, hyperemic and enlarged spleen, 
lymphadenopathy, and petechial hemorrhage within the renal cortices, urinary bladder, 
epicardium, endocardium, and pleura (Gomez-Villamandos et al., 1995; Sánchez-Vizcaíno et al., 
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2015). Once an outbreak is established the disease course tends to shift from acute to subacute, 
and over longer periods of time (as in endemic areas) chronic and subclinical disease may be 
observed (Allaway et al., 1995; Fasina et al., 2010; Owolodun et al., 2010). Subacute disease 
presents with more mild clinical signs and mortality ranges from 30 to 70% with survivors 
recovering in 3 to 4 weeks after infection (Sánchez-Vizcaíno et al., 2015). Chronic ASF has been 
primarily associated with lower virulence strains, and it has been proposed that the chronic 
disease seen in the Iberian peninsula from 1960 through the 1990s was a consequence of live 
attenuated vaccine use (Sánchez-Vizcaíno et al., 2012). Exposure to a low dose of highly virulent 
virus may delay the onset of disease, but mortality is not decreased. Petrov et al. reported that 
sentinel pigs remained ASFV negative when co-mingled with convalescent pigs at 99 days post-
challenge with ASFV Netherlands86. Virus was successfully isolated from clinical samples 
collected from the challenged animals at 48 days post infection (dpi), and viral genome 
detectable in blood at 91dpi (Petrov et al., 2018). It is impossible to say if this result was due to a 
decline in infectiousness of the convalescent animals, or if 30 animals was not a large enough 
sample size to demonstrate what may be a rare transmission event. In direct contrast, Eblé et al. 
reported that transmission from carrier animals resulted in new acute cases when naïve pigs were 
co-mingled with animals recovered from ASFV Netherlands86 at 28-41dpi or 42-55dpi (Eblé et 
al., 2019). One consideration from these studies is that variation in virus strain will have an 
impact on the outcome of infection and the number of animals that survive and may become 
carriers. The genotype I ASFV strain Netherlands86, is considered moderately virulent, but the 
currently circulating genotype II strain is highly virulent. Despite this, the detection of antibody 
positive wild boar in Russia and eastern Europe indicates a population of animals are surviving 
infection (Mur et al., 2016; Nurmoja et al., 2017; Woźniakowski et al., 2016). Although the 
percent of positive samples are low, it indicates the possibility of feral swine acting as long term 
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carriers of the disease. Even in the absence of long-term carrier animals the appearance of less 
prominent forms of the disease, such as chronic and subacute, may play a role in persistence and 
spread. In addition to various forms of ASF, other diseases such as classical swine fever and 
erysipelas can mimic ASF. As such, a presumptive clinical diagnosis by an observant producer 
or veterinarian must be confirmed with both virologic and serologic diagnostic methods. 
 Diagnostics and surveillance 
The diversity of ASF clinical presentation makes laboratory diagnosis an essential tool 
for disease surveillance and control. It is important to utilize both virus and antibody detection 
methods. For conducting diagnosis and surveillance, the preferred methods are real-time PCR for 
the detection of nucleic acid and ELISA for detecting antibodies.  
 Virologic assays 
PCR is preferred because it is rapid, specific and can detect ASFV prior to the appearance 
of clinical signs. In surviving pigs, virus can persist for months, making PCR practical as a long-
term testing strategy. The principal drawbacks of PCR include high cost and the requirement of 
expensive equipment for conducting high throughput screening. The OIE describes validated 
methods for both conventional and real-time PCR tests (Fernández-Pinero et al., 2013; Tignon et 
al., 2011). Currently the US has limited testing capabilities, with the USDA National Animal 
Health Laboratory Network (NAHLN) having 11 labs approved to test for ASF. The USDA 
estimates that at current capacity only 6,500 PCR samples could be run per day, with whole 
blood and tonsil being the only approved samples (the USDA is working to validate testing of 
oral fluids). For reference, the USDA quarterly estimated the pig population in the United States 
to be 75.5 million animals as of June 27, 2019 and a single large farm may have more than 5,000 
pigs (USDA, 2019a). In the face of an epidemic where rapid largescale testing is crucial for 
disease control measures, our current testing capabilities would likely prove insufficient. Other 
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available antigen tests include direct fluorescent antibody test (FAT) and enzyme-linked 
immunosorbent assay (ELISA), though PCR has widely replaced these two assays and been 
demonstrated as more specific than antigen detecting ELISA (C. Gallardo et al., 2015). Though 
antigen capture ELISA is not as sensitive as PCR, it is useful for efficient screening at the herd 
level (C. Gallardo et al., 2019). The p72 capsid antigen is an ideal target for ASFV antigen 
detection because it is conserved among strains and highly immunogenic. Among the 68 proteins 
that comprise the virion, p72 accounts for 10% of the antigen mass (Alejo et al., 2018). While 
antigen tests are a useful diagnostic tool, one clear shortfall is that detecting viral DNA does not 
equate to infectious virus. Based on the OIE manual, virus isolation remains the preferred 
method for ASFV identification, but it is impractical. Propagation of ASFV requires primary 
swine leukocytes which are time consuming and expensive to obtain, and their use comes with 
ethical concerns related to animal use. In addition ASFV is a foreign animal disease that is 
regulated by the federal select agent program (FSAP) in the US, thus few facilities have the 
biocontainment requirements and expertise to propagate live virus. When virus isolation is 
performed, hemadsorption (HAD) reaction is commonly assessed. HAD is the term for the 
binding of erythrocytes and rosette formation, a phenomenon not seen with other swine 
pathogens and an indicator of an ASFV positive sample. It is important to note that some strains 
of ASFV do not cause HAD, and an additional confirmatory antigen test such as FAT should be 
executed on HAD negative samples. HAD testing is the OIE gold standard diagnostic, but is 
performed in limited amounts due to facility requirements, time required (7-10 days), need for 
highly trained staff, and cost. 
 Serologic assays 
In contrast, serologic tests are inexpensive and relatively easy to perform. In the absence 
of available vaccines antibody presence is always indicative of exposure, though it’s worth 
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noting that acute disease may lead to death before detectable levels of antibodies are produced. 
The technique of choice for antibody detection is ELISA with a follow up test such as 
immunoblotting (IB), indirect fluorescent antibody (IFA), or immunoperoxidase (IPT) to confirm 
positive samples. ELISA is a fast and low cost test, but confirmatory testing is important  
because incorrectly handled or stored sera can yield false positive results. IPT is more sensitive 
than ELISA and capable of detecting lower antibody titers, but is more labor intensive, costly, 
and requires use of live virus (M. C. Gallardo et al., 2015). To detect antibodies, IPT utilizes 
antigens produced on plates of cells infected with ASFV. The main limitation of IPT is the strict 
requirements required by the FSAP to remove inactivated ASFV from BSL-3 containment. This 
bars the notion of sending prepared and fixed plates for IPT to standard diagnostic laboratories in 
an efficient manner. Table 1.1 provides a brief overview of current ASF diagnostic methods. 
Diagnostic tools for use in the field are available, but show limited sensitivity compared to gold 
standard laboratory methods (C. Gallardo et al., 2019). These are useful for emergency response, 
but not as standalone test. Active surveillance is another tool that until recently, was missing 
from our diagnostic strategy. In May 2019 the USDA announced the addition of ASF to the 
previously existing CSF surveillance program. The USDA began CSF surveillance in March 
2006 with a goal of testing targeted populations based on the following criteria: swine suspicious 
for CSF, sick pigs submitted to a veterinary diagnostic lab, pigs condemned at slaughter, feral 
swine, and swine in herds considered high risk. The selection criteria will remain the same, but 
the samples will now be tested for both CSF and ASF. While we have the tools to confidently 
diagnose ASF, we lack the ability to reach that confidence in a rapid manner and at the capacity 
necessary for rapid response to an outbreak. Performing multiple diagnostic tests takes time, as 
does the requirement to send samples to approved testing facilities. An accurate diagnosis is a 
multifaceted approach that should include virologic and serologic results within the context of 
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the clinical and epidemiological characteristics being observed in the field. Rapid response and 
diagnosis is key to handling an outbreak, particularly in the absence of other prophylactic 
measures. 
 Integration of existing knowledge into a biosecure US swine industry 
If ASFV enters the US there are several points of concern from a biosecurity standpoint, 
such as limiting domestic pig and wild boar contact, controlling spread of virus by human 
activities, and management of environmental virus persistence. The diagram in Figure 3 
illustrates the biosecurity challenges facing the US swine industry. According to a 2006 survey 
by the USDA APHIS, over half of farrowing, nursery, and grower/finisher sites keep pigs under 
total confinement, with the majority of these sites using some form of all-in/all-out management. 
Despite this, the US has seen recent outbreaks of swine diseases, such as the introduction and 
rapid spread of porcine epidemic diarrhea virus (PEDV). PEDV entered the United States in 
2013 and led to the death of approximately 7 million pigs over the next year. The disease spread 
quickly throughout the Midwest, with epidemiological analysis suggesting that transport 
equipment was a major contributing risk factor (Bowman et al., 2015). Though the PEDV 
outbreak was primarily among domestic pigs, other outbreaks have spread via contact between 
feral and domestic pigs, such as brucellosis in New York in 2016. Such examples indicate that 
the US pig industry is still highly susceptible to outbreaks caused by new pathogens. One novel 
system under development is known as The Secure Pork Supply (SPS), a collaborative plan 
between swine producers, state and federal government officials, Iowa State University, and the 
University of Minnesota (www.securepork.org). The SPS is a voluntary program that ensures the 
implementation of disease prevention and outbreak preparedness with the goal of minimizing 
interruptions to business.  Aspects of the SPS plan include enhanced biosecurity practices, 
designation of individuals who will manage surveillance and sample collection, a diagnostic 
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sample submission plan, and maintenance of accurate animal movement records. An example of 
some of the higher level biosecurity practices required by the SPS is an establishment of a 
perimeter buffer area and implementation of lines of separation with designated access points. 
The software and database for the SPS, when completed for use, will compile and share real-time 
industry data to provide the most up to date information on swine health status and disease 
outbreaks.  
 Conclusion 
Although ASF is not present in the US, the scope of the current global outbreak has 
drawn considerable attention to the disease. ASF is devastating to the swine industry in affected 
areas, and remains difficult and expensive to control. Much is still unknown about barriers to 
infection, viral protein functions, and host-virus interactions. Further research is needed on these 
topics, with a particular focus on processes that occur early in replication, such as cell entry. The 
scope of this research was to evaluate virus entry pathways, compare a surrogate virus (vaccinia) 
to ASFV, and reevaluate the controversial role of CD163 in ASFV cell entry.  
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Figure 1.1 African swine fever dissemination in China 
ASF spread rapidly throughout China following its introduction in August 2018. By February 13, 
2019, the affected regions included: Liaoning, Henan, Jiangsu, Zhejiang, Anhui, Heilongjiang, 
Inner Mongolia, Jilin, Tianjin, Shanxi, Yunnan, Hunan, Guizhou, Chongqing, Jiangxi, Fujian, 
Hubei, Sichuan, Shangai, Beijing, Shaanxi, Qinghai, Guangdong, Guansu, Ningxia 
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Figure 1.2 African swine fever dissemination in Vietnam 
ASF spread rapidly throughout Vietnam following its introduction in February 2019 and by June 
the majority of the country was affected, leading to the culling of almost 3 million pigs. 
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Figure 1.3 ASFV structure based on tissue culture adapted BA71V strain 
The localization of 40 viral proteins among the five structural domains of the ASFV particle is 
shown. The distribution of proteins marked with an asterisk was inferred from the predicted or 
known role. Figure from (Alejo et al., 2018). 
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Figure 1.4 Model for ASFV internalization and uncoating 
ASFV enters swine macrophages by clathrin-mediated endocytosis (left) and constitutive 
macropinocytosis (right). After the uptake, incoming particles are transported from early 
endosomes or macropinosomes to late endosomes, where they undergo a pH dependent 
uncoating process. Then, the exposed inner viral envelope fuses with the endosomal membrane 
to deliver genome-containing naked cores into the cytosol. Figure from (Hernáez et al., 2016) 
used under CC BY 4.0.  
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Table 1.1 African swine fever diagnostic techniques 
Modified from: African swine fever: detection and diagnosis – A manual for veterinarians 
(Beltrán-Alcrudo et al., 2017) 
Assay 
(Virological) 
Time Cost Sample required Comments 
Polymerase chain 
reaction (PCR) 
4-6 hours Medium Tissues, blood, 
ticks, cell culture 
supernatant 
Common 
methodology. 
Nucleic acid 
detected may be 
from live or dead 
virus. 
Hemadsorption 
(HAD) test 
7-21 days High Primary porcine 
cell culture 
Gold standard. 
Limited number 
of facilities can 
perform.  
Fluorescence 
antibody test 
1-2 hours High  Tissues: 
cryosection or 
impression smear. 
Requires 
florescence 
microscope. 
Reagent 
availability 
limited. Not 
routinely used. 
ELISA 3-4 hours Low Serum, tissue Not routinely 
used. 
Assay 
(Serological) 
Time Cost Sample required Comments 
ELISA 3-4 hours Low Serum Recommended 
screening test 
Immunoblotting 3-4 hours High Serum Confirmatory test. 
No commercial 
kits.  
Indirect 
fluorescent 
antibody test 
3-4 hours Medium Serum, Plasma, 
Tissue. Requires 
florescence 
microscope  
Confirmatory test. 
No commercial 
kits. 
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Table 1.2 Infectivity of various ASFV doses and strains when administered orally, nasally, 
or intraoropharyngeally 
ASFV can be transmitted orally or intranasally with varying results depending on dose and 
strain. Using intranasal inoculation doses as low as 101 are capable of causing infection, while 
Malta78 achieved 100% infection at 104 and Tegani at 105. Oral inoculation seems to be less 
efficient, with Tanzania KWH/12 and Hinde WH II requiring a dose of 107 to achieve 100% 
infection. 
 
ASFV Strain  Route Dose % infection Reference 
Armenia 2008  Oronasal 101 to 102 25% Pietschmann 2015  
Malawi 1983   Intraoropharyngeally 102 0% Howey 2013  
Malawi 1983   Intranasopharyngeally  102 50% Howey 2013  
 
Dominican Republic 
1979 
 Intranasal/oral 102.6 0% McVicar 1984 
East Africa  Intranasal 102.9 50% Parker 1969, reviewed in Guinat 2016  
East Africa  Intranasal 102.9 Minimum ID Plowright 1969  
Malta'78  Intranasal 103 60% de Carvalho Ferreira 2012, de Carvalho 
Ferreira 2013 
Netherlands  Intranasal 103 60% de Carvalho Ferreira 2013 
Netherlands  Intranasal 103.5 60% de Carvalho Ferreira 2012 
Dominican Republic 
1979 
 Intranasal/oral 103.6 13% McVicar 1984 
East Africa; tissues 
from naturally-infected warthogs 
 Liquid or moistened solid feed 103.7-106.1  0% Plowright 1969   
Unknown  Intranasal 103.7 – 103.9 100% Plowright 1969 
Tanzania KWH/12  Spleen given orally in milk 104 0% Greig 1972 
Netherlands  Intranasal 104 60% de Carvalho Ferreira 2013 
Malta'78  Intranasal 104 100% de Carvalho Ferreira 2012 
Malta'78  Intranasal 104 100% de Carvalho Ferreira 2013 
Brazil  Intranasal 104.5 100% de Carvalho Ferreira 2012 
Dominican Republic 
1979 
 Intranasal/oral 104.6 88% McVicar 1984 
Malawi 1983   Intranasopharyngeally 104 to 106 100% Howey 2013  
Malawi 1983   Intraoropharyngeally  104 to 106 100% Howey 2013  
Tanzania KWH/12  Spleen given orally in milk 105 37.5% Greig 1972   
Unknown  Oral feeding (pig tissues) 105 Minimum ID Maurer 1954, reviewed in Heuschele 
1967 
Tengani strain  Intranasal 105 100% Heuschele 1967 
Dominican Republic 
1979 
 Intranasal/oral 105.6 90% McVicar 1984 
Tanzania KWH/12  Spleen given orally in milk 106 75% Greig 1972 
Tanzania KWH/12  Spleen given orally in milk 107 100% Greig 1972 
Hinde WH II   Oral inoculation of infective blood 107-107.5 100% Colgrove 1969 
Hinde WH II  Minced spleen and liver added to feed 107-107.5 100% Colgrove 1969 
Tanzania KWH/12  Spleen given orally in milk 108 100% Greig 1972 
Kenya 
  
  
 Oral (Contaminated feces & urine) Not known 100% Montagomery 1921, reviewed in Guinat 
2016 
Kenya  Oral (Contaminated sweet potatoes or 
bananas) 
Not known 0% Montagomery 1921, reviewed in Guinat 
2016 
Georgia   Oral fresh grass and seeds 
contaminated by secretions from infectious wildboar 
Not known Epidemiological 
evidence; unknown dose 
EC 2014, reviewed in Guinat 2016 
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Table 1.3 Distribution of CD163 positive macrophages in the most commonly studied 
human tissues 
The presence of subpopulations of CD163 positive macrophages has not been studied in swine, 
but could make a difference in ASFV infection. Adapted from (Fabriek et al., 2005). 
 
Tissue Macrophage subpopulation CD163  
Spleen Red pulp macrophages + 
 Perifollicular macrophages - 
Lymph nodes Medullary macrophages + 
 Perifollicular macrophages + 
Thymus Medullary macrophages + 
 Cortical macrophages + 
Liver Kupffer cells + 
Brain Perivascular macrophages + 
 Meningeal macrophages + 
 Microglia - 
Lung Alveolar macrophages + 
 Interstitial macrophages + 
Blood Monocytes + (10-30%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
28 
Chapter 2 - Vaccinia virus as a model for African swine fever virus 
entry 
 Introduction 
African swine fever is a unique virus and thus exists in its own family, but this was not 
always the case. ASFV was in family Iridoviridae until it was removed to an unassigned genus, 
African swine fever virus group (later renamed African swine fever-like viruses). In 1998 the 
genus was renamed to Asfivirus and assigned to family Asfarviridae (International Committee on 
Taxonomy of Viruses. et al., 1995; Simmonds et al., 2018). ASFV is classified as a 
nucleocytoplasmic large DNA virus (NCLDV), which are a group of apparently monophyletic 
viruses that include the following families: Ascoviridae, Asfarviridae, Iridoviridae, 
Marseilleviridae, Mimiviridae, Phycodnaviridae, and Poxviridae. ASFV has intermediate 
properties of both family Poxviridae and Iridoviridae. These three virus families all encode their 
own transcription machinery, including RNA polymerase subunits, transcription factors, and 
share a large number of conserved genes (Tidona & Darai, 1997; Yáñez et al., 1995).  
Poxviruses are a family of complex viruses characterized by a large linear dsDNA 
genome, a complex enveloped structure, and cytoplasmic replication. They are some of the 
largest animal viruses and may be visualized using light microscopy. Poxviridae is split into two 
subfamilies, Chordopoxvirinae and Entomopoxvirinae. Sub-family Chordopoxvirinae contains 
the genus Orthopoxvirus, which includes vaccinia virus, variola virus, and monkeypox virus. 
While some poxviruses, such as variola, are host specific, others are zoonotic and can infect 
multiple species. Vaccinia virus (VV) is one such zoonotic member of Orthopoxvirus, known 
primarily for its role in smallpox vaccination. Vaccinia virus has been identified as a desirable 
surrogate for ASFV because of the similarities between ASFV and poxviruses. Vaccinia virus is 
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widely used and readily available, is not a select agent, and does not require high containment 
laboratory space.  
Vaccinia virus has a 195kb genome that encodes nearly 200 proteins, and is considered 
the prototypical poxvirus. Despite being the most studied orthopoxvirus, the origin and natural 
hosts of vaccinia virus remain unknown. Some hypotheses include evolution from variola virus, 
evolution from cowpox virus, a hybridization of variola and cowpox, or the extinction of a 
species that acted as a natural vaccinia reservoir (Bedson & Dumbell, 1964; Elwood, 1989). 
ASFV and VV have genomic and structural similarities, with some equivalent genes involved in 
nucleic acid modification and replication (Yáñez et al., 1995). Both viruses are large, enveloped 
DNA viruses that primarily replicate in the cell cytoplasm and package many of their required 
enzymes. Their extensive viral transcriptional machinery provides a degree of independence 
from host processes and control over viral gene expression. Homology between the two viruses 
is referenced to support predictions of ASFV protein functions. Mature vaccinia virions have 
several proteins associated with the poxviral entry/fusion complex, including A16, A21, A28, 
F9, G3, G9, H2, J5, L1, and L5 (Sobhy, 2017a). These entry/fusion complex proteins mediate 
virus-cell fusion and membrane disruption. Four of these proteins share structural and sequence 
closeness with two ASFV transmembrane proteins. ASFV pE248R is similar to VV protein L1 
and ASFV pE199L is similar to VV proteins G9, A16, and J5 (Germán Andrés, 2017; Hernáez et 
al., 2016). Another example of similarity is the shared ability of ASFV and VV to modulate and 
interfere with host immune responses, such as blocking interferon and regulating cell death. 
ASFV pE152R contains a complement control module/short consensus sequence domain that is 
also found in the VV proteins BR5 and VCP (Manuel V. Borca et al., 2016). BR5 and VCP act 
to inhibit complement activation (Bernet et al., 2011; Rosengard et al., 1999). Vaccinia 
demonstrates some of the same immune evasion tactics used by ASFV, such as regulation of 
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interferon, inflammation, and apoptosis (Nichols et al., 2017; Smith et al., 2018). ASFV and VV 
both have complex replication cycles that produce multiple forms of infectious particles. 
Vaccinia mature virus (MV) particles are surrounded by one membrane, while extracellular 
enveloped virus (EV) are surrounded by an additional membrane obtained during cell egress 
(Hollinshead et al., 1999). It has been proposed that this host-derived membrane may aid in 
evading host antibodies and complement. The majority of infectious particles are MV, which 
remain within the cell until lysis (Smith et al., 2018). A small portion of MV particles give rise to 
intracellular enveloped virions (IEV) which are triple enveloped particles wrapped by a trans-
Golgi derived membrane-cisterna (Schmelz et al., 1994). EV and MV particles contain different 
sets of viral proteins in their outer envelopes, but due to the majority of particles being MV and 
the fragility of the EV outer membrane, most studies of vaccinia have focused on MV (Ichihashi, 
1996).  
Knowledge of specific host-cell receptors that interact with poxviruses is limited, though 
some relevant cellular proteins have been evaluated. Studies from multiple groups have reported 
on the role of cellular glycosaminoglycans during MV attachment and entry. Chung et al. first 
reported the ability of vaccinia to interact with heparin sulfate (HS), with binding occurring 
between HS and VV proteins A27 and H3 (Chung et al., 1998; Lin et al., 2000). Chondroitin 
sulfate, another glycosaminoglycan, is reported to interact with the viral protein D8 and HeLa 
cells lacking glycosaminoglycans are less susceptible to VV infection (Chung et al., 1998; Hsiao 
et al., 1999; Lin et al., 2000). The lipid raft associated protein CD98 has also been found to play 
a role in viral entry, with infection rate being reduced 50% in HeLa cells with CD98 knockdown 
(Sobhy, 2017b). CD98 is an amino acid transport and cell adhesion glycoprotein expressed by 
most cell types (Verrey et al., 2000). Some genes have been identified as poxviral host-range 
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genes, with the E3L and K3L genes of vaccinia being the best characterized (Seet et al., 2003). 
These proteins both play a role in immune evasion.  
Unlike many other viruses, poxvirus tropism at the cellular level seems to be regulated by 
downstream intracellular events, instead of by receptors at the level of binding and entry. Viral 
entry into both permissive and restrictive cells has been observed, but replication is abortive in 
the latter (Johnston et al., 2003). An example of this can be seen using K3L deletion mutant VV, 
which undergoes abortive infection specifically in BHK-21 cells (Beattie et al., 1995; Langland 
& Jacobs, 2002). As such, poxviruses can enter a wide variety of mammalian cells, but 
permissiveness to replication varies between cell lines and virus strain. General mechanisms of 
viral entry include virus-cell fusion, cell-cell fusion, and endocytosis. There are several 
endocytic pathways, including phagocytosis, pinocytosis, and receptor-dependent pathways. 
Vaccinia has primarily been reported to enter cells via macropinocytosis, however there are 
contrasting reports surrounding VV entry mechanisms, which may be explained by variations 
between both the virus strain and cell type used. HeLa, BHK-21, and BSC-1, are three 
commonly used cell lines with VV. Vaccinia virus entry into HeLa and BSC40 (a variant cell 
line derived from BSC-1) cells has been described as using a dynamin-dependent endocytic 
pathway, or dynamin-independent macropinocytosis (Huang et al., 2008; Mercer & Helenius, 
2008b).  
The poxvirus intracellular replication cycle has been most studied on vaccinia, but 
essential features are highly conserved within the virus family. Once inside the cell, both ASFV 
and VV rely on microtubules for intracellular transport to the site of uncoating and formation of 
viral factories (Carter, 2003; Hernaez et al., 2006). Though vaccinia virus interactions with Vero 
cells are less studied, differences from other cell lines have been reported. Viral kinetics are cell 
type dependent, with Vero cell entry occurring faster than other cell lines. Whitbeck et al. 
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reported that entry into Vero cells was detectable by 3 minutes, versus 6 to 9 minutes for HeLa 
and BSC-1 cells. Similar to ASFV, vaccinia can utilize a low pH dependent endosomal entry 
pathway with infectivity enhanced in BSC-1 cells at a pH between 4 and 4.5 (Townsley et al., 
2006). However, compared to HeLa and BSC-1 cells, vaccinia entry into Vero cells is less 
sensitive to inhibition using bafilomycin, an inhibitor of endosomal acidification (Whitbeck et 
al., 2009). This suggests that in some cells VV may utilize both pH-dependent and pH-
independent pathways. Such alternate pathways may be responsible for the faster rate of entry 
into Vero cells. We hypothesized that vaccinia will exhibit similar cell entry characteristics into 
Vero cells as BA71V, the Vero adapted strain of ASFV.  
 Materials and Methods 
Cells and viruses.  
Vero (ATCC CCL-81) cells were purchased from the American Type Culture Collection 
(ATCC). BHK-21 cells (ATCC CCL-10) and a green fluorescent protein (GFP) tagged vaccinia 
virus were kindly provided by Zhilong Yang of the Division of Biology at Kansas State 
University. DH82 (ATCC CRL-10389) were kindly provided by Roman Ganta of the Division of 
Diagnostic Medicine and Pathobiology at Kansas State University. The Vero adapted strain of 
African swine fever virus BA71V was previously grown in our lab. All cell cultures were 
maintained in a humid incubator at 37°C containing 5% CO2. DH82 cells and BHK-21 cells 
were maintained in minimum essential medium with Earle’s salts and L-glutamine (Corning #10-
010-CM) and supplemented with penicillin/streptomycin (Gibco #15070063) at 160 U/mL, 
amphotericin B (Gibco #15290026) at 3 ug/mL, and 10% fetal bovine serum. Vero cells were 
maintained in minimum essential medium with Earle’s salts and L-glutamine and supplemented 
with penicillin/streptomycin (160 U/mL), amphotericin B (3 ug/mL), and 7% fetal bovine serum. 
Vaccinia virus stocks were produced using BHK-21 cells.  After 48-72 hours, infected cells were 
33 
detached using a cell scraper and pelleted using low speed centrifugation, lysed by rapid freezing 
and thawing following resuspension of the pellet, vortexed, and aliquoted and stored at -80C° as 
previously described (Reeder et al., 2016). Prior to use, each batch of harvested virus was tested 
via endpoint dilution to determine the TCID50/mL as calculated using the Spearman-Karber 
method (Hierholzer & Killington, 1996).  
 Cell inhibitor compounds 
Seven inhibitory compounds were used in this study (Table 2.1). All compounds were 
reconstituted in DMSO and stored in aliquots at -20°C. EIPA (Tocris Bioscience CAS#1154252) 
was stored as a 5 mM solution. Chlorpromazine (Sigma-Aldrich CAS#69090) was stored as a 50 
mM solution. Cytochalasin D (Sigma-Aldrich CAS #22144770), ML-7 (Sigma Aldrich 
CAS#110448334), and Wortmannin (Cayman Chemical CAS#19545267) were stored as 1 mM 
solutions. Nocodazole (Cayman Chemical CAS#31430189) and Dynasore (Cayman Chemical 
CAS#304448553) were stored as 5 mM solutions.  
 Cell Viability  
Viability of chemically treated cells was determined using MTT [3-(4,5-dimethylthiazol-
2- yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. MTT (Cayman 
Chemical CAS#57360697) was reconstituted in sterile PBS to a stock concentration of 5 mg/mL 
and stored in single use aliquots at -20°C. A 96 well plate of cells was treated with a range of 
concentrations of each chemical inhibitor and incubated at 37°C and 5% CO2 for 6 hours. 
Following incubation the media containing drug was removed from all wells. Cells were washed 
once with sterile PBS and then 100 uL of fresh media containing 0.5 mg/mL of MTT reagent 
was added. Cells were incubated at 37°C and 5% CO2 for 3-4 hours until purple formazan 
crystals visualized. The MTT reagent containing media was removed and 100 uL of 100% 
DMSO added to dissolve the crystals. After 10 to 15 minutes of incubation the optical density 
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was recorded at 570nm using a microplate reader. Reported results are from two experiments 
with each sample tested in duplicates.  
 Fluorescently labeled dextran uptake 
Fluorescently labeled dextran (ThermoFisher, Alex Fluor 488, 10000MW, anionic, 
fixable) was reconstituted using sterile PBS to a 2 mg/mL solution and stored in aliquots at  
-20°C. DH82 cells were treated with concentrations of dextran ranging from 6.25 ug/mL to 200 
ug/mL and incubated for 24 hours. The cells were observed under a fluorescence microscope at 
various timepoints to visualize particle internalization. All incubation was done in an incubator at 
37°C and 5% CO2. EIPA was used to examine the ability to inhibit macropinocytosis and the 
fluid phase uptake of dextran particles. DH82 cells or Vero cells were treated with 
concentrations of EIPA ranging from 25uM to 1000uM. After a 30 minute incubation 200 ug/mL 
of dextran was added. After 30 a further minutes of incubation the cells were washed with PBS 
and fixed for 10 minutes using 4% paraformaldehyde. The number of fluorescent particles was 
counted in the cells observed in two microscope fields and represented as the average number of 
particles per cell.  
 Vaccinia virus infection inhibition 
24 well plates of 70-80% confluent cells were treated with the each inhibitor across a 
range of concentrations (see Table 2.1). Following treatment, cells were incubated for 30 
minutes. Cells were then infected with 105 TCID50 of VV or ASFV BA71V. Treated and 
infected cells were incubated for 6 hours at 37C and 5% CO2. The media was then removed. 
Cells were washed once with sterile PBS, and fresh media was added. Following a 24 hour 
incubation at 37C and 5% CO2 cells were fixed, stained, and counted under a fluorescence 
microscope. Vero cells infected with BA71V were fixed with 4% paraformaldehyde for 10 
minutes at room temperature followed by a 7 minute permeabilization at room temperature with 
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0.2% saponin. Cells were stained using a monoclonal p30 antibody at 1:6000 dilution for 1 hour 
at 37°C or overnight at 4°C (Petrovan et al., 2019). Goat anti-mouse IgG Alexa Fluor 488 was 
used as the secondary antibody at 1:400 dilution for 1 hour at 37°C. DAPI was used as a counter 
stain prior to viewing with a fluorescence microscope. BHK-21 cells and Vero cells infected 
with VV-GFP were fixed with 4% paraformaldehyde and permeabilized with 0.2% saponin. 
Fixed cells were incubated with PureLink RNase A at 100ug/mL for 20 minutes at room 
temperature, followed by counterstaining with Propidium Iodide at 1:3000 dilution for five 
minutes. Following staining cells were viewed with a fluorescence microscope. The number of 
cells and the number of infected cells were determined from an average of three randomly 
selected fields of view from each well. Reported results are from two experiments with each 
sample tested in duplicates. Error bars represent standard error between experiments. Statistical 
significance was calculated using the student’s t-test (* = p ≤ .05, ** = p ≤ .01, *** = p ≤ .001). 
 Results 
 Cell viability 
The cytotoxicity of the seven selected compounds was evaluated based on MTT assay 
after cells were treated for six hours. This time interval was chosen because six hours was the 
viral absorption period used in virus inhibition experiments. As seen in Figures 2.1 and 2.2 some 
of the lower concentration treatments show a viability of over 100% as compared to untreated 
controls. This is a fairly common result with the MTT assay due to random experimental 
fluctuation and possible stimulation by the treatment. Hormesis is a common toxicologic 
phenomenon that describes a biphasic dose response characterized by stimulation at low doses 
and inhibition or toxicity at high doses (Calabrese & Baldwin, 2002). This observed low dose 
stimulation may be due to a direct effect of the compound or due to a stress related compensatory 
response (Calabrese et al., 2007). A compensatory response to a stressor may increase cellular 
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metabolism of MTT. Unlike hormesis, direct chemical reduction of MTT by tested compounds 
often leads to excessively high viability values (>500%). Figure 2.3 shows the MTT results for 
the selected concentrations that are represented on the virus inhibition figures.  
 Fluorescently labeled dextran uptake 
Dextran was used as a surrogate particle in early experiments in order to observe 
macropinocytosis occurring in cells. Uptake of fluorescent dextran occurred rapidly, with 
intracellular particles visible as early as 5 minutes after the addition of dextran to cells. While 
both cell lines underwent fluid-phase uptake of dextran particles, based on the number of 
particles the endocytic activity appears higher in DH-82 cells than Vero cells. Both cell lines 
demonstrate a dose dependent decrease in particle uptake when treated with EIPA, though the 
inhibitory effect appears to be more potent in DH-82 cells.  
 Vaccinia virus inhibition in BHK-21 cells 
Treatment with nocodazole and EIPA showed a significant decrease in infection. 
 Vaccinia virus and ASFV BA71V inhibition in Vero cells 
 Chlorpromazine 
Chlorpromazine (CPZ) is commonly used in cell culture as an inhibitor of clathrin-
mediated endocytosis. It is a cationic amphipathic drug believed to inhibit formation of the 
clathrin coated-pit by interfering with binding between clathrin it’s associated adapter proteins  
(Wang et al., 1993). In Vero cells, treatment with CPZ up to 15uM did not significantly alter 
infection with BA71V. VV infection was reduced when cells were treated with 1.875uM of CPZ.  
 EIPA 
5-(N-ethhyl-n-isopropil)- amiloride (EIPA) is an inhibitor of the Na+/H+ exchanger and 
commonly used as an inhibitor of macropinocytosis because it exerts minimal effect on other 
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endocytic processes. Vero cells treated with EIPA showed a decrease in infection rate of both 
VV and BA71V, consistent with macropinocytosis involvement in cell entry.  
 Cytochalasin D 
Cytochalasin D (Cyto D) is a cell permeable fungal toxin that binds to the barbed ends of 
actin filaments. It disrupts actin filaments, and inhibits actin polymerization (Miranda et al., 
1974). Cyto D disrupts the entry of both viruses, as it affects macropinocytosis due to the role 
actin plays in the formation and trafficking of macropinosomes.  
 Wortmannin 
Wortmannin is a PI3 kinase inhibitor reported to reduce fluid-phase uptake via 
macropinocytosis (Araki et al., 1996). Despite the percent decrease of both BA71V and VV 
infected cells as compared to the control, due to variance between the samples the p-value was 
not significant.  
 Dynasore 
The large GTPase dynamin is essential for clathrin-dependent vesicle formation during 
clathrin-mediate endocytosis (Kirchhausen et al., 2008). However, dynasore has also been 
described as having additional effects, such as reducing labile cholesterol in the cell membrane 
and disrupting lipid raft organization (Preta et al., 2015). Infection of both viruses was reduced in 
Vero cells treated with dynasore.  
 ML-7 
ML-7 is a selective myosin light chain kinase (MLCK) inhibitor (Gao, Li-Hong Ye, 
Hiroko Kishi, Tsuy, 2001). MLCK phosphorylates the regulatory light chain of myosin II. Non-
muscle myosin II plays a role in a number of cell processes including clathrin-mediated 
endocytosis and has recently been described as a potential therapeutic target during infection by 
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pathogenic organisms (Chandrasekar et al., 2014; Tan et al., 2019). Treatment of Vero cells with 
ML-7 reduced infection with both ASFV and BA71V.   
 Nocodazole 
Nocodazole is a drug that depolymerizes microtubules and can disrupt early endosomal 
movement. Treatment of Vero cells with nocodazole led to inhibition of ASFV infection, but not 
VV.  
 Discussion 
BHK-21 cells were used to propagate Vaccinia virus and were also tested with the 
inhibitors. The effect of dynasore is ambiguous with some studies reporting it to influence cell 
entry (Huang et al., 2008) and others finding it does not (Mercer & Helenius, 2008a). Despite a 
mean reduction in infection of 30%, the decrease was not found to be significant (p = 0.54). As 
expected, the Na+/H+ antiporter inhibitor EIPA produced the most pronounced effect on 
infection.  
While BHK-21 is a cell line that is fairly commonly used with Vaccinia virus, Vero cells 
have been less studied with this virus. The inhibitor results suggest that VV is capable of 
utilizing both clathrin-dependent endocytosis and macropinocytosis when entering Vero cells. 
Though most studies have reported macropinocytosis as the primary entry pathway for Vaccinia 
virus, there are known variances. For example, infection of CHO cells is not affected by 
macropinocytosis inhibitors such as EIPA and wortmannin, suggesting alternative entry 
pathways (Mercer et al., 2010).  
Failure of chlorpromazine to reduce BA71V infection in Vero cells, as well as the 
inhibitory effect of EIPA and wortmannin, suggests that macropinocytosis is the primary entry 
pathway for BA71V into Vero cells. Prior reports have identified chlorpromazine inhibition of 
clathrin as not interfering with ASFV entry, but affecting late viral protein synthesis. In contrast, 
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dynasore, another inhibitor that effects endosomal fusion and receptor-mediated endocytosis, 
does reduce ASFV infection in Vero cells. One possible explanation is due to additional potential 
effects of dynasore (such as affecting plasma membrane cholesterol) being responsible for the 
virus interference. It is also possible that clathrin-mediated endocytosis is occurring, and usage 
of a higher dose of CPZ would have produced a more profound inhibitory effect. Using a higher 
dose would likely necessitate a shorter treatment period to limit cytotoxicity. The reduced 
infection of VV seen following treatment of Vero cells with chlorpromazine or dynasore 
suggests a higher sensitivity to disruption of clathrin- and dynamin-dependent endocytosis than 
BA71V. It has also been reported that in HeLa cells, Vaccinia recruits clathrin to stimulate actin-
motility for virus transport following fusion, which could play a role in its inhibitory effect 
(Humphries et al., 2012). The novel use of ML-7 with VV and ASFV also led to decreased 
infection rates with both viruses. This indicates that myosin II activity is involved in early 
infection of Vero cells with VV and ASFV BA71V.  
While there are some apparent differences in interactions with the host cell during early 
infection, overall the effects induced by the tested inhibitors was fairly consistent between the 
two viruses. Future studies can appropriately use VV as a model for ASFV, but should consider 
the possible variance in the cellular processes utilized during early infection. Further evaluation 
of VV entry pathways into Vero cells or macrophages should evaluate later steps (such as the 
role of endosomal acidification and late viral protein synthesis) and would do well to incorporate 
additional testing methodologies, such as flow cytometry. Vaccinia virus infection in primary 
macrophages may present a better model for ASFV which still alleviates the need for BSL-3 
space, but does introduce the drawback of using primary cells. Vaccinia virus will replicate in 
swine macrophages and Hernáez et al reported that VV infection on macrophages was unaffected 
by treatment with CPZ, but information beyond that are limited (Hernáez et al., 2016). 
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Describing effective surrogate models for ASFV is useful due to the barriers for working 
with virulent ASFV. Virulent strains of ASFV require primary macrophages which are time 
consuming to collect and have a finite lifespan in culture. Use of the virus also requires BSL-3 
containment in most regions and is strictly regulated. Vaccinia virus as a surrogate virus allows 
for work to proceed in BSL-2, which requires less cost, time, and regulation. Knowledge of viral 
and cellular factors involved in the stages of early infection can help to develop new antiviral 
strategies.  
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Figure 2.1 BHK-21 cell viability based on MTT 
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Figure 2.2 Vero cell viability based on MTT 
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Figure 2.3 BHK-21 cell treatments with >93% viability on MTT 
 
 
 
Figure 2.4 Vero cell treatments with >95% viability on MTT 
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Figure 2.5 Cellular uptake and inhibition of fluorescent dextran on DH82 cells 
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Figure 2.6 Inhibition of dextran uptake in DH82 cells 
 
 
 
Figure 2.7 Inhibition of dextran uptake in Vero cells 
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Figure 2.8 Vaccinia virus inhibition on BHK-21 cells 
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Figure 2.9 Vaccinia virus inhibition on Vero cells 
(* = p ≤ .05, ** = p ≤ .01, *** = p ≤ .001) 
 
 
Figure 2.10 ASFV BA71V inhibition on Vero cell 
(* = p ≤ .05, ** = p ≤ .01, *** = p ≤ .001) 
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Figure 2.11 Fluorescence microscopy of Vero and BHK-21 cells infected with Vaccinia 
virus 
 
  
49 
Table 2.1 Inhibitor information 
 
 
 
 
Compound 
 
 
 
 
Target(s) 
 
 
 
 
Range of concentrations used 
in uM 
 
 
Maximum 
 
 
Minimum 
EIPA Na+/H+ antiport 50 1.5625 
Cytochalasin D Actin polymerization 10 0.3125 
Wortmannin Phosphatidylinositol-3 kinase 10 0.3125 
Chlorpromazine Adaptor protein-2 30 0.9375 
Dynosore dynamin1, 2, DRP1 100 3.125 
ML-7 Myosin 25 0.78125 
Nocodazole Microtubule formation 50 1.5625 
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Chapter 3 - ASFV cell entry: macrophages and CD163 
 Introduction 
African swine fever virus is a large double-stranded DNA virus and the only member of 
the family Asfarviridae (International Committee on Taxonomy of Viruses. et al., 1995). With a 
diameter of approximately 200nm it is a structurally large icosahedral shaped virus. The ASFV 
genome is between 170 and 190Kb and encodes for over 150 proteins. The virus consists of an 
outer envelope, capsid, inner envelope, and core shell surrounding the nucleoid (Salas & Andrés, 
2013). Monocytes and macrophages are the main cellular targets of ASFV, however the specific 
cellular receptor(s) involved in viral entry and tissue tropism are unknown (Oura et al., 1998; F. 
Rodriguez et al., 1996). Macrophages from other species, such as humans, rabbits, guinea pigs, 
hamsters, and rats show no effect from the virus (Enjuanes et al., 1977). Macrophages play an 
important role in normal homeostasis and have activity during pathologic conditions such as 
infection and inflammation. Mature tissue macrophages are capable of phagocytizing and 
destroying foreign materials, and producing inflammatory mediators. The infectious cycle begins 
with viral attachment and entry into the host cell. Early studies comparing virulent and tissue 
culture adapted strains found that the entry mechanism is a low pH- and temperature-dependent 
process, which is consistent with specific receptor-mediated endocytosis (A Alcamí et al., 1990; 
Antonio Alcamí et al., 1989). However, receptor mediated-endocytosis appears to be necessary 
but not sufficient for viral infection (Carrascosa et al., 1999). CD163 is one receptor that has 
been purported to play a role in ASFV cell entry, but researchers have come to varying 
conclusions. CD163 is a scavenger receptor cysteine-rich domain (SRCR). SRCR domains are a 
subset of scavenger receptors, which are cell surface glycoproteins. CD163 is highly expressed 
on macrophages and is a known receptor for other pathogens, namely PRRVS. The best 
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characterized biological function of CD163 is the binding and clearance of hemoglobin-
haptoglobin complexes. Free hemoglobin is oxidative, so this clearance process not only protects 
against damage, but may also provide a pathway for iron uptake and recycling in macrophages.   
A handful of studies have evaluated the role of CD163 during ASFV infection. Sánchez-
Torres et al first reported in 2003 that CD163 expression correlated with infection, and that the 
anti-pig CD163 monoclonal antibody 2A10 is able to inhibit ASFV binding and infection of 
PAMs (Sánchez-Torres et al., 2003). Yet later studies have found contradictory results, such as 
the inability of stable CD163 expression to allow infection in non-permissive cells (Lithgow et 
al., 2014). Genetically modified pigs with a complete knockout of CD163 also show no 
resistance to disease when challenged with virulent ASFV (Popescu et al., 2017). In addition, the 
ability of ASFV to replicate in cells that do not express CD163 during late infection also 
suggests alternative receptors or entry pathways. Together, this data shows that CD163 is not 
required for ASFV infection, but does not rule out its involvement. Despite a lack of consensus 
on which cellular factors are involved, a receptor-dependent endocytic process is believed to play 
a role in ASFV cell entry. It is now known that another entry mechanism used by ASFV is 
macropinocytosis. When treated with the macropinocytosis inhibitor, Ethylisopropyl amiloride 
(EIPA), cells show a dose-dependent reduction in ASFV uptake (Sánchez et al., 2012). 
Macropinocytosis is a non-specific cellular process for the uptake of various molecules, in which 
they are engulfed and endocytosed into vacuoles termed macropinosomes. While a variety of cell 
types can utilize macropinocytosis it is usually transient in response to growth factors, except for 
immune cells such as dendritic cells and macrophages which can constitutively undergo 
macropinocytosis (Racoosin & Swanson, 1992; Sallusto, 1995). Some viruses that utilize 
macropinocytosis are known to induce the process, but current evidence is more suggestive that 
ASFV utilizes constitutive cellular pathways (Hernáez et al., 2016; Lim & Gleeson, 2011). 
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ASFV’s use of multiple entry pathways may be what allows the virus to infect alternate cell 
types during late stages of infection, such as hepatocytes, epithelial cells, and endothelial cells 
(Germán Andrés, 2017; Valli, 2007). Another alternative pathway that has been proposed is 
antibody-dependent enhancement, where antibodies facilitate cell entry via Fc or complement 
receptors. Despite ASFV utilizing non-specific mechanisms of cell entry, it is alleged that other 
factors contribute to its host and cellular specificity, such as an undiscovered protein interaction 
between the host and virus. We hypothesize that though it is not required, CD163 does play a 
role in ASFV cell entry, and that treatment with cellular inhibitors (particularly inhibitors that 
affect macropinocytosis) will reflect a difference in virus infection rates between wildtype and 
CD163 knockout macrophages.  
 Materials and Methods 
Cells and viruses.  
Pulmonary alveolar macrophages (PAMs) were collected via lung lavage. Three 
approximately four week old pigs were humanely euthanized by IV injection of pentobarbital. 
The pluck was carefully removed and the trachea incised distal to the tongue. The excised lungs 
were filled with 150mL to 300mL of cold sterile PBS poured from 50mL conical tubes. 
Following massage of the lungs, the liquid is poured back out into the sterile tubes and placed on 
ice until processing. Cells are pelleted via centrifugation at 500xg for 5 minutes, then washed 
once with sterile PBS and pelleted again. Pelleted cells were resuspended in freezing media 
(RPMI + 50% FBS + 10% DMSO), frozen at -80°C, then moved to liquid nitrogen for long term 
storage. CD163KO PAMs were harvested in the same manner from CD163KO pigs that were 
generated using in-vitro fertilization of oocytes edited by CRISPR-Cas9. See Whitworth et al 
2014 for more information (Whitworth et al., 2014). Cell cultures were maintained in a humid 
incubator at 37°C containing 5% CO2. PAMs were maintained in RPMI with L-glutamine 
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(Corning #10-040-CM) and supplemented with penicillin/streptomycin (Gibco #15070063) at 72 
U/mL, amphotericin B (Gibco # 15290026) at 3 ug/mL, and 10% fetal bovine serum. Spleen 
homogenate from a pig infected with African swine fever Gerogia07 during a prior animal study 
was used as the source of virus. 
 Cell inhibitor compounds 
Seven inhibitory compounds were used in this study (Table 2.1). All compounds were 
reconstituted in DMSO and stored in aliquots at -20°C. EIPA (Tocris Bioscience CAS#1154252) 
was stored as a 5 mM solution. Chlorpromazine (Sigma-Aldrich CAS#69090) was stored as a 50 
mM solution. Cytochalasin D (Sigma-Aldrich CAS #22144770), ML-7 (Sigma Aldrich 
CAS#110448334), and Wortmannin (Cayman Chemical CAS#19545267) were stored as 1 mM 
solutions. Nocodazole (Cayman Chemical CAS#31430189) and Dynasore (Cayman Chemical 
CAS#304448553) were stored as 5 mM solutions.  
 Cell Viability  
Viability of chemically treated cells was determined using MTT [3-(4,5-dimethylthiazol-
2- yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. MTT (Cayman 
Chemical CAS#57360697) was reconstituted in sterile PBS to a stock concentration of 5 mg/mL 
and stored in single use aliquots at -20°C. A 96 well plate of cells was treated with increasing 
concentrations of each chemical inhibitor and incubated at 37°C and 5% CO2 for 6 hours or 24 
hours. Following incubation the media containing drug was removed from all wells and replaced 
with 100 uL of fresh and untreated media containing 0.5 mg/mL of MTT reagent. Cells were 
then incubated at 37°C and 5% CO2 for 3-4 hours until purple formazan crystals were visualized. 
The MTT reagent containing media was removed and 100 uL of 100% DMSO added to dissolute 
the crystals. After 10 to 15 minutes of incubation the optical density was recorded at 570nm 
54 
using a microplate reader. Reported results are from two experiments with each sample tested in 
duplicates.  
 Inhibition of ASFV infection on PAMs 
96 well plates of PAMs were treated with the each inhibitor across a range of 
concentrations (see Table 2.1). Following treatment, cells were incubated for 30 minutes. Cells 
were then infected with a 1:100 dilution of ASFV Georgia07 spleen homogenate. Treated and 
infected cells were incubated for 6 hours at 37C and 5% CO2. The media was then removed and 
replaced with fresh media. Following a 48 hour incubation at 37C and 5% CO2 cells were fixed, 
stained, and counted under a fluorescence microscope. PAMs infected with Georgia07 were 
fixed with 4% paraformaldehyde for 10 minutes at room temperature followed by a 7 minute 
permeabilization at room temperature with 0.2% saponin. Cells were stained using a monoclonal 
p30 antibody at 1:6000 dilution or anti-CD163 (Mouse anti-pig 2A10) antibody at 1:100 dilution 
for 1 hour at 37°C or overnight at 4°C (Petrovan et al., 2019). Goat anti-mouse IgG Alexa Fluor 
488 was used as the secondary antibody and incubated at 1:400 dilution for 1 hour at 37°C. 
DAPI was used as a counter stain prior to viewing with a fluorescence microscope. An 
automated program was used to image three randomly selected fields per well. The number of 
cells and the number of infected cells were determined from the images. The total number of 
cells in each image was counted using the analyze particles macro in ImageJ, while the number 
of infected cells was manually counted. Error bars represent standard error between experiments. 
Statistical significance was calculated using the student’s t-test (* = p ≤ .05, ** = p ≤ .01, *** = 
p ≤ .001). 
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 Results 
 Cell viability 
The cytotoxicity of the seven selected compounds was evaluated based on MTT assay 
after cells were treated for six hours. This time interval was chosen because six hours was the 
viral absorption period used in virus inhibition experiments. As seen in Figures 3.1 and 3.2 some 
of the lower concentration treatments show a viability of over 100% as compared to untreated 
controls. This is a fairly common result with the MTT assay due to random experimental 
fluctuation and possible stimulation by the treatment. Hormesis is a common toxicologic 
phenomenon that describes a biphasic dose response characterized by stimulation at low doses 
and inhibition or toxicity at high doses (Calabrese & Baldwin, 2002). This observed low dose 
stimulation may be due to a direct effect of the compound or due to a stress related compensatory 
response (Calabrese et al., 2007). A compensatory response to a stressor may increase cellular 
metabolism of MTT. Unlike hormesis, direct chemical reduction of MTT by tested compounds 
often leads to excessively high viability values (>500%).  
 Inhibition of ASFV infection on PAMs 
 Chlorpromazine 
Chlorpromazine (CPZ) is commonly used in cell culture as an inhibitor of clathrin-
mediated endocytosis. It is a cationic amphipathic drug believed to inhibit formation of the 
clathrin coated-pit by interfering with binding between clathrin it’s associated adapter proteins  
(Wang et al., 1993). Treatment of PAMs with 15uM of CPZ reduced the rate of infection of 
ASFV in both WT and CD163KO cells. However, there was no statistically significant 
difference between the relative percent infection of the two cell types.  
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 EIPA 
5-(N-ethhyl-n-isopropil)- amiloride (EIPA) is an inhibitor of the Na+/H+ exchanger and 
commonly used as an inhibitor of macropinocytosis because it exerts minimal effect on other 
endocytic processes. Treatment of PAMs with 25uM or 50uM of EIPA reduced the rate of 
infection of ASFV in both WT and CD163KO cells. However, there was no statistically 
significant difference between the relative percent infection of the two cell types. 
 Cytochalasin D 
Cytochalasin D (Cyto D) is a cell permeable fungal toxin that binds to the barbed ends of 
actin filaments. disrupts actin filaments, and inhibits actin polymerization (Miranda et al., 1974). 
Cyto D disrupts the entry of both viruses, as it affects macropinocytosis due to the role actin 
plays in the formation and trafficking of macropinosomes. Treatment of PAMs with 10uM of 
Cyto D reduced the rate of infection of ASFV in both WT and CD163KO cells. However, there 
was no statistically significant difference between the relative percent infection of the two cell 
types. 
 Wortmannin 
Wortmannin is a PI3 kinase inhibitor reported to reduce fluid-phase uptake via 
macropinocytosis (Araki et al., 1996). Treatment of PAMs with 10uM of wortmannin reduced 
the rate of infection of ASFV in both WT and CD163KO cells. However, there was no 
statistically significant difference between the relative percent infection of the two cell types. 
 Dynasore 
The large GTPase dynamin is essential for clathrin-dependent vesicle formation during 
clathrin-mediate endocytosis (Kirchhausen et al., 2008). However, dynasore has also been 
described as having additional effects, such as reducing labile cholesterol in the cell membrane 
and disrupting lipid raft organization (Preta et al., 2015). Infection of both cell types was reduced 
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following treatment with dynasore, but there was not a significant difference between the 
knockout and wildtype cells.  
 ML-7 
ML-7 is a selective myosin light chain kinase (MLCK) inhibitor (Gao, Li-Hong Ye, 
Hiroko Kishi, Tsuy, 2001). MLCK phosphorylates the regulatory light chain of myosin II. Non-
muscle myosin II plays a role in a number of cell processes including clathrin-mediated 
endocytosis and has recently been described as a potential therapeutic target during infection by 
pathogenic organisms (Chandrasekar et al., 2014; Tan et al., 2019). Treatment of both WT and 
CD163KO PAMs with ML-7 reduced infection with ASFV Georgia07, but with no significant 
difference in the relative infection rates of the two groups.  
 Nocodazole 
Nocodazole is a drug that depolymerizes microtubules and can disrupt early endosomal 
movement. Treatment of cells with nocodazole led to inhibition of ASFV infection, but there was 
no significant difference between wildtype and CD163KO macrophages.   
 Discussion 
Although at this time the evidence is fairly substantial that CD163 is not required for 
ASFV infection, there remains uncertainty if it is has any involvement with infection. While 
ASFV infection has been observed in other cell types, particularly during late stages of disease, 
the mechanism behind the viral tropism for swine macrophages remains unknown. The question 
remains if there is a specific cellular receptor that is crucial to cellular permissiveness to ASFV, 
or as if theorized with Vaccinia, tropism is primarily defined by post-entry events. We aimed to 
examine if there is a difference between wildtype and CD163KO PAMs in the virus-host 
interactions that occur during cell entry and early infection. The inhibitors used do not appear to 
affect cell viability differently between WT and CD163KO PAMs. While the viability curve 
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generated by MTT results does have some variation, at the concentrations reported for the 
inhibition experiments there is no statistically significant difference between the two cell types. 
Overall, macrophages were tolerant to higher concentrations of treatments than other cell lines 
tested.  
ASFV enters macrophages using macropinocytosis and dynamin- and clathrin- dependent 
endocytosis. As expected, all of the inhibitors inhibited ASFV in macrophages, including the 
MLCK inhibitor ML-7. Despite the observed lower relative percentage of infection in the 
CD163KO PAMs, none of the differences were calculated to be statistically significant. 
Ultimately this aligns with the current paradigm of early infection, and suggests that CD163 is 
not involved at all with ASFV cell entry and early infection. While this study did not examine 
the inhibitor affects for the duration of infection, with CD163 being a cell surface protein it 
seems less likely to play a role beyond early infection. Future studies should focus on other 
cellular receptors that may be involved in ASFV entry, and cellular factors required for 
permissiveness to infection.  
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Figure 3.1 PAMs viability based on MTT 
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Figure 3.2 CD163 Knockout PAMs viability based on MTT 
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Table 3.1 Comparison of wildtype and CD163KO MTT results 
Results were not found to be significantly different between the two cell types, suggesting the 
gene knockout does not play a role in cellular response and viability when treated. 
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Figure 3.3 ASFV Georgia07 inhibition on WT PAMs 
(* = p ≤ .05, ** = p ≤ .01, *** = p ≤ .001) 
 
 
 
Figure 3.4 ASFV Georgia07 inhibition on CD163KO PAMs 
(* = p ≤ .05, ** = p ≤ .01, *** = p ≤ .001) 
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Figure 3.5 Wild type PAMs infected with ASFV Georgia07 stained with anti-p30 antibody 
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Figure 3.6 Wild type PAMs (uninfected) stained with anti-CD163 antibody 
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Chapter 4 - Concluding remarks 
African swine fever virus currently presents the greatest risk to global swine health. Since 
the introduction of the disease into Georgia in 2007, the virus has seen unprecedented global 
spread and has affected many countries throughout Europe and Southeast Asia. As a result of the 
outbreak trade has been impacted and millions of animals have been destroyed, leading to 
significant economic impact. Transcontinental spread of the virus is believed to have occurred 
due to the movement of contaminated garbage and pork products, with wild boar contributing to 
the spread of disease in Eastern Europe.  
Due to the complexity of the virus, there is still only a basic understanding of viral 
pathogenesis and host immunity. Two notable challenges of working with ASFV include the 
regulatory requirements of the virus, and the need for primary cells. Similarities between 
Asfarviridae and Poxviridae have led to Vaccinia virus to be identified as a useful surrogate for 
ASFV. However, VV has been little evaluated in Vero cells compared to other cell lines. While 
VV may be more sensitive to the disruption of clathrin- and dynamin-dependent endocytosis 
than BA71V, overall their response to the inhibitors suggests similar behavior during cell entry 
and early infection. Vaccinia may prove a useful surrogate for future studies, and can be used 
with both Vero cells and primary porcine macrophages.  
While it is understood that ASFV uses macropinocytosis, the cause of ASFV’s tropism is 
unknown. Clathrin-mediated endocytosis is also purported to be involved in cell entry, with 
CD163 being a proposed receptor. Studies have found contradictory results, though it is safe to 
say that CD163 is not required for infection. This work took that a step further to try to answer if 
CD163 is involved in infection at all. The CD163KO macrophages showed a similar response to 
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the inhibitors used, with all seven reducing the percent of infected cells relative to the untreated 
control. This corroborates that ASFV enters cells using both macropinocytosis and clathrin- and 
dynamin-dependent endocytosis, and utilizes non-muscle myosin II and microtubules during 
stages of entry and early infection. Ultimately, the lack of a significant difference in inhibition of 
virus infection between the wildtype and CD163 knockout macrophages suggests that CD163 
has no involvement in ASFV infection. Unfortunately, this still leaves us with the pressing 
question: if not CD163 then what receptors, if any, are involved in ASFV infection? ASFV 
continues to remain an agricultural pathogen of high concern and a serious potential threat. Many 
aspects of ASFV’s pathogenesis are not yet understood, which adds to the challenge of 
developing treatments or vaccines. Continued research efforts are necessary to determine 
receptors that are important to ASFV replication, and factors that regulate viral tropism.   
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